Get the Stockscreener App
3.49
5.44%
+0.18
Alimera Sciences Inc. stock is currently priced at $3.49, with a 24-hour trading volume of 17,332.
It has seen a +5.44% increased in the last 24 hours and a -9.82% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.41 pivot point. If it approaches the $3.55 resistance level, significant changes may occur.
Previous Close:
$3.31
Open:
$3.28
24h Volume:
17,332
Market Cap:
$182.72M
Revenue:
$80.75M
Net Income/Loss:
$-20.13M
P/E Ratio:
-1.327
EPS:
-2.63
Net Cash Flow:
$-89.79M
1W Performance:
+4.49%
1M Performance:
-9.82%
6M Performance:
+7.22%
1Y Performance:
+74.50%
1D Range:
$3.28
$3.50
52W Range:
$1.56
$4.38
Alimera Sciences Inc. Stock (ALIM) Company Profile
Name
Alimera Sciences Inc.
Sector
Phone
678 990 5740
Address
6310 Town Square, Suite 400, Alpharetta, GA
Alimera Sciences Inc. Stock (ALIM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-19 | Initiated | Craig Hallum | Buy |
| Apr-27-17 | Initiated | Rodman & Renshaw | Buy |
| Nov-17-14 | Initiated | Summer Street Research | Buy |
| Sep-29-14 | Reiterated | Northland Capital | Outperform |
| Oct-28-13 | Upgrade | Cowen | Market Perform → Outperform |
| Oct-08-13 | Initiated | Northland Capital | Outperform |
| Nov-14-11 | Downgrade | Rodman & Renshaw | Mkt Outperform → Mkt Perform |
| Dec-27-10 | Reiterated | Oppenheimer | Outperform |
| Oct-11-10 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-02-10 | Initiated | Oppenheimer | Outperform |
View All
Alimera Sciences Inc. Stock (ALIM) Latest News
New Strong Sell Stocks for March 13th
Zacks Investment Research
Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Novavax (NVAX) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Alimera Appoints Maggie A. Pax to Its Board of Directors
GlobeNewswire Inc.
Alimera Sciences Inc. Stock (ALIM) Financials Data
Alimera Sciences Inc. (ALIM) Revenue 2024
ALIM reported a revenue (TTM) of $80.75 million for the quarter ending December 31, 2023, a +49.19% rise year-over-year.
Alimera Sciences Inc. (ALIM) Net Income 2024
ALIM net income (TTM) was -$20.13 million for the quarter ending December 31, 2023, a -11.18% decrease year-over-year.
Alimera Sciences Inc. (ALIM) Cash Flow 2024
ALIM recorded a free cash flow (TTM) of -$89.79 million for the quarter ending December 31, 2023, a -777.74% decrease year-over-year.
Alimera Sciences Inc. (ALIM) Earnings per Share 2024
ALIM earnings per share (TTM) was -$2.1622 for the quarter ending December 31, 2023, a +16.52% growth year-over-year.
About Alimera Sciences Inc.
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
1.69%
1.28%
Cap:
|
Volume (24h):